PATENT CLAIM ANALYSIS

Application Number: 16022031
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-02
Patent Classification: ["514", "234500"]

Abstract:
The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R 4 , R 5 , and R 6  are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Claim (Index 27):
The compound of  claim 1 , selected from:\n 2-(1H-imidazol-2-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 2-(1H-imidazol-5-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(1H-pyrrol-2-yl)benzo[d]oxazole; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 2-(1H-indol-2-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-methoxypyridin-3-yl)benzo[d]thiazole; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-methoxypyridin-3-yl)quinoline; 2-(6-bromo-1H-benzo[d]imidazol-2-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 2-(5-fluoro-1H-benzo[d]imidazol-2-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(5-methyl-1H-benzo[d]imidazol-2-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(4-methyl-1H-benzo[d]imidazol-2-yl)benzo[d]oxazole; 2-(1H-benzo[d]imidazol-2-yl)-6-bromobenzo[d]oxazole; 5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-ol; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-isopropoxypyridin-3-yl)benzo[d]oxazole; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-(difluoromethoxy)pyridin-3-yl)benzo[d]oxazole; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)ethanesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)-3-fluorobenzenesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)piperidine-1-sulfonamide; N\u2032-{5-[2-(1H-benzimidazol-2-yl)-1,3-benzoxazol-6-yl]-pyridin-3-yl}-N,N-dimethylsulfamide; N\u2032-{5-[2-(1H-benzimidazol-2-yl)-1,3-benzoxazol-6-yl]-2-methylpyridin-3-yl}-N,N-dimethylsulfamide; N\u2032-{5-[2-(1H-benzimidazol-2-yl)-1,3-benzoxazol-6-yl]-2-fluoropyridin-3-yl}-N,N-dimethylsulfamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)propane-2-sulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-methylpyridin-3-yl)ethanesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-chloropyridin-3-yl)ethanesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-fluoropyridin-3-yl)ethanesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-methylpyridin-3-yl)-4-fluorobenzenesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-chloropyridin-3-yl)-4-fluorobenzenesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-fluoropyridin-3-yl)-4-fluorobenzenesulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)-4-methylpiperazine-1-sulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-2-fluoropyridin-3-yl)-4-methylpiperazine-1-sulfonamide; N-(5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)acetamide; 5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)-N,N-dimethylpyridin-3-amine; 5-(2-(1H-benzo[d]imidazol-2-yl)benzo[d]oxazol-6-yl)nicotinonitrile; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-(methylsulfonyl)pyridin-3-yl)benzo[d]oxazole; 5-[2-(1H-benzimidazol-2-yl)-1,3-benzoxazol-6-yl]-N,N-dimethylpyridine-3-sulfonamide; 2-(1H-benzo[d]imidazol-2-yl)-6-(5-(morpholinosulfonyl)pyridin-3-yl)benzo[d]oxazole; N-(5-(2-(1H-imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide; N-(5-(2-(1H-imidazol-2-yl)benzo[d]oxazol-6-yl)pyridin-3-yl)ethanesulfonamide; N\u2032-{5-[2-(1H-imidazol-2-yl)-1,3-benzoxazol-6-yl]pyridin-3-yl}-N,N-dimethylsulfamide; 2-(2-cyclopropyl-1H-imidazol-5-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(2-(tetrahydrofuran-3-yl)-1H-imidazol-5-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(2-phenyl-1H-imidazol-5-yl)benzo[d]oxazole; 2-(2-ethyl-1H-imidazol-5-yl)-6-(5-methoxypyridin-3-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(3-methyl-1H-pyrazol-5-yl)benzo[d]oxazole; 6-(5-methoxypyridin-3-yl)-2-(3-phenyl-1H-pyrazol-5-yl)benzo[d]oxazole; or a pharmaceutically acceptable salt of any of the aforementioned.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.55769
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15019144', '13854789', '12972155', '15631417', '15065409']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7992435724186576
- 35 USC 102 Novelty (BERT): 0.571268681392959
- Combined Prediction Score: 0.7764460833160878
- Mean Citation Score: 379.18514
- Max Citation Score: 453.30923
- Similarity Product: 423.5152247581792

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test